Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore Ltd. (Nasdaq and Tel Aviv: PLSM), joins host Tim Gerdeman and WTR equity research analyst James Kisner on this episode of the WTR Small-Cap Spotlight Podcast. Pulsenmore has built the first FDA De Novo–authorized, prescription home-use prenatal ultrasound, allowing expectant mothers to capture images on a handheld device for remote physician review.
Sonnenschein walks through the company’s journey from concept to creating an entirely new regulatory category, what it takes to deliver a home scan clinicians can trust, and how years of real-world use shaped the platform. The conversation explores Pulsenmore’s U.S. commercial launch, its proving ground in Israel, and a broader women’s health strategy that now extends into fertility and IVF monitoring. He also shares his perspective on scaling the business and what investors should be watching over the year ahead.
Podden och tillhörande omslagsbild på den här sidan tillhör
Water Tower Research. Innehållet i podden är skapat av Water Tower Research och inte av,
eller tillsammans med, Poddtoppen.
